Table 3.
Distribution frequency of the clinical status and MMP-11 rs738792 genotype frequencies in 479 CRC patients.
| Variable | All (N = 479) | Rectum (N = 110) | Colon (N = 369) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TT (N = 241) |
TC + CC (N = 238) |
p Value | TT (N = 60) |
TC + CC (N = 50) |
p Value | TT (N = 181) |
TC + CC (N = 188) |
p Value | |
| Stages | |||||||||
| I + II | 115 (47.7%) | 114 (47.9%) | p = 0.892 | 31 (51.7%) | 29 (58.0%) | p = 0.482 | 84 (46.4%) | 85 (45.2%) | p = 0.945 |
| III + IV | 126 (52.3%) | 124 (52.1%) | 29 (48.3%) | 21 (42.0%) | 97 (53.6%) | 103 (54.8%) | |||
| Tumor T status | |||||||||
| T1 + T2 | 62 (25.7%) | 54 (22.7%) | p = 0.805 | 20 (33.3%) | 16 (32.0%) | p = 0.569 | 42 (23.2%) | 38 (20.2%) | p = 0.885 |
| T3 + T4 | 179 (74.3%) | 184 (77.3%) | 40 (66.7%) | 34 (68.0%) | 139 (76.8%) | 150 (79.8%) | |||
| Lymph node status | |||||||||
| Negative | 119 (49.4%) | 120 (50.4%) | p = 0.630 | 32 (53.3%) | 30 (60.0%) | p = 0.411 | 87 (48.1%) | 90 (47.9%) | p = 0.643 |
| Positive | 122 (50.6%) | 118 (49.6%) | 28 (46.7%) | 20 (40.0%) | 94 (51.9%) | 98 (52.1%) | |||
| Metastasis | |||||||||
| Negative | 204 (84.6%) | 198 (83.2%) | p = 0.955 | 46 (76.7%) | 45 (90.0%) | p = 0.090 | 158 (87.3%) | 153 (81.4%) | p = 0.212 |
| Positive | 37 (15.4%) | 40 (16.8%) | 14 (23.3%) | 5 (10.0%) | 23 (12.7%) | 35 (18.6%) | |||
| Lymphovascular invasion | |||||||||
| No | 136 (56.4%) | 131 (55.0%) | p = 0.457 | 38 (63.3%) | 33 (66.0%) | p = 0.830 | 98 (54.1%) | 98 (52.1%) | p = 0.426 |
| Yes | 105 (43.6%) | 107 (45.0%) | 22 (36.7%) | 17 (34.0%) | 83 (45.9%) | 90 (47.9%) | |||
| Perineural invasion | |||||||||
| No | 147 (61.0%) | 125 (52.5%) | p = 0.051 | 39 (65.0%) | 34 (68.0%) | p = 0.998 | 108 (59.7%) | 91 (48.4%) | p = 0.025 a |
| Yes | 94 (39.0%) | 113 (47.5%) | 21 (35.0%) | 16 (32.0%) | 73 (40.3%) | 97 (51.6%) | |||
| Cell differentiation | |||||||||
| Well/Moderately | 227 (94.2%) | 216 (90.8%) | p = 0.164 | 60 (100%) | 49 (98.0%) | ----- | 167 (92.3%) | 167 (88.8%) | p = 0.323 |
| Poorly | 14 (5.8%) | 22 (9.2%) | 0 (0.0%) | 1 (2.0%) | 14 (7.7%) | 21 (11.2%) | |||
a AOR (95% CI):1.783 (1.074–2.960). The adjusted odds ratios (AORs) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for stages, tumor T status, lymph node status, metastasis, lymphovascular invasion, perineural invasion, and cell differentiation.